nach oben

European Journal of Epidemiology

Erschienen in:

22.06.2018 | COMMENTARY

A new era for dementia epidemiology: Alzheimer’s disease, hardening of arteries, or just old age?

verfasst von: Lewis H. Kuller

Erschienen in: European Journal of Epidemiology | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Excerpt

The paper by Glymour et al. questions the recently published research framework for the diagnosis of Alzheimer’s disease (AD) for research studies [1]. Their interpretation of the role of amyloid in the diagnosis of AD is inaccurate and has led them to a faulty interpretation of the need for these new guidelines [2]. …

Glymour M, Brickman AM, Kivimaki M, Mayeda ER, Chene G, Dufouil C, Manly JJ. Will biomarker-based diagnosis of Alzheimer’s disease maximize scientific progress? Evaluating proposed diagnostic criteria. Eur J Epidemiol. 2018. https://doi.org/10.1007/s10654-018-0418-4.PubMedCrossRef

Jack CR Jr., Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement J Alzheimer’s Assoc. 2018;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018.CrossRef

Ganguli M, Dodge HH, Chen P, Belle S, DeKosky ST. Ten-year incidence of dementia in a rural elderly US community population: the MoVIES project. Neurology. 2000;54(5):1109–16.CrossRefPubMed

Gilsanz P, Mayeda ER, Glymour MM, et al. Female sex, early-onset hypertension, and risk of dementia. Neurology. 2017;89(18):1886–93. https://doi.org/10.1212/WNL.0000000000004602.CrossRefPubMed

Cadar D, Lassale C, Davies H, Llewellyn DJ, Batty GD, Steptoe A. Individual and area-based socioeconomic factors associated with dementia incidence in England: evidence from a 12-year follow-up in the English longitudinal study of ageing. JAMA Psychiatry. 2018. https://doi.org/10.1001/jamapsychiatry.2018.1012.PubMedCrossRefPubMedCentral

Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science. 2006;314(5800):777–81. https://doi.org/10.1126/science.1132814.CrossRefPubMed

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44.CrossRefPubMed

Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the cardiovascular health study. J Am Geriatr Soc. 2004;52(2):195–204.CrossRefPubMed

Lopez OL, McDade E, Riverol M, Becker JT. Evolution of the diagnostic criteria for degenerative and cognitive disorders. Curr Opin Neurol. 2011;24(6):532–41. https://doi.org/10.1097/WCO.0b013e32834cd45b.CrossRefPubMedPubMedCentral

10.

Kuller LH, Lopez OL, Jagust WJ, et al. Determinants of vascular dementia in the cardiovascular health cognition study. Neurology. 2005;64(9):1548–52. https://doi.org/10.1212/01.WNL.0000160115.55756.DE.CrossRefPubMedPubMedCentral

11.

Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197–204. https://doi.org/10.1212/01.wnl.0000271090.28148.24.CrossRefPubMed

12.

Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55(3):306–19. https://doi.org/10.1002/ana.20009.CrossRefPubMed

13.

Silverberg N, Elliott C, Ryan L, Masliah E, Hodes R. NIA commentary on the NIA-AA research framework: towards a biological definition of Alzheimer’s disease. Alzheimer’s Dement J Alzheimer’s Assoc. 2018;14(4):576–8. https://doi.org/10.1016/j.jalz.2018.03.004.CrossRef

14.

Mormino EC, Betensky RA, Hedden T, et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760–7. https://doi.org/10.1212/WNL.0000000000000431.CrossRefPubMedPubMedCentral

15.

Burnham SC, Bourgeat P, Dore V, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol. 2016;15(10):1044–53. https://doi.org/10.1016/S1474-4422(16)30125-9.CrossRefPubMed

16.

Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924–38. https://doi.org/10.1001/jama.2015.4668.CrossRefPubMedPubMedCentral

17.

Stern Y. An approach to studying the neural correlates of reserve. Brain Imaging Behav. 2017;11(2):410–6. https://doi.org/10.1007/s11682-016-9566-x.CrossRefPubMedPubMedCentral

18.

Lopez OL, Becker JT, Chang Y, et al. Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. Neurology. 2018;90(21):e1920–8. https://doi.org/10.1212/WNL.0000000000005549.CrossRefPubMed

19.

Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957–65. https://doi.org/10.1016/S1474-4422(13)70194-7.CrossRefPubMedPubMedCentral

20.

Yang FM, Grigorenko A, Tommet D, et al. AD pathology and cerebral infarctions are associated with memory and executive functioning one and five years before death. J Clin Exp Neuropsychol. 2013;35(1):24–34. https://doi.org/10.1080/13803395.2012.740001.CrossRefPubMed

21.

Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–96. https://doi.org/10.1056/NEJMra023144.CrossRefPubMed

22.

Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004;10(10):1055–63. https://doi.org/10.1038/nm1113.CrossRefPubMed

23.

Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804. https://doi.org/10.1056/NEJMoa1202753.CrossRefPubMedPubMedCentral

24.

Benzinger TL, Blazey T, Jack CR Jr., et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci USA. 2013;110(47):E4502–9. https://doi.org/10.1073/pnas.1317918110.CrossRefPubMed

25.

Donahue JE, Johanson CE. Apolipoprotein E, amyloid-beta, and blood–brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol. 2008;67(4):261–70. https://doi.org/10.1097/NEN.0b013e31816a0dc8.CrossRefPubMed

26.

Kuller LH, Lopez OL. Dementia and Alzheimer’s disease: a new direction. The 2010 Jay L. Foster memorial lecture. Alzheimer’s Dement J Alzheimer’s Assoc. 2011;7(5):540–50. https://doi.org/10.1016/j.jalz.2011.05.901.CrossRef

27.

Jackrel ME, Shorter J. Protein-remodeling factors as potential therapeutics for neurodegenerative disease. Front Neurosci. 2017;11:99. https://doi.org/10.3389/fnins.2017.00099.CrossRefPubMedPubMedCentral

28.

Goudsmit J. The incubation period of Alzheimer’s disease and the timing of tau versus amyloid misfolding and spreading within the brain. Eur J Epidemiol. 2016;31(2):99–105. https://doi.org/10.1007/s10654-016-0144-8.CrossRefPubMedPubMedCentral

29.

Dubnikov T, Cohen E. The emerging roles of early protein folding events in the secretory pathway in the development of neurodegenerative maladies. Front Neurosci. 2017;11:48. https://doi.org/10.3389/fnins.2017.00048.CrossRefPubMedPubMedCentral

30.

Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–20. https://doi.org/10.1016/j.jacc.2016.06.033.CrossRefPubMed

31.

Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94. https://doi.org/10.1093/eurheartj/ehv338.CrossRefPubMed

32.

Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007;13(9):1029–31. https://doi.org/10.1038/nm1635.CrossRefPubMedPubMedCentral

33.

Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR. AD brain pathology: vascular origins? Results from the HAAS autopsy study. Neurobiol Aging. 2008;29(10):1587–90. https://doi.org/10.1016/j.neurobiolaging.2007.03.008.CrossRefPubMed

34.

Gottesman RF, Schneider AL, Zhou Y, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443–50. https://doi.org/10.1001/jama.2017.3090.CrossRefPubMedPubMedCentral

35.

George DR, Whitehouse PJ, D’Alton S, Ballenger J. Through the amyloid gateway. Lancet. 2012;380(9858):1986–7.CrossRefPubMed

36.

Traynor BJ, Rademakers R. Dementia research-A roadmap for the next decade. JAMA Neurol. 2017;74(2):141–2. https://doi.org/10.1001/jamaneurol.2016.5004.CrossRefPubMedPubMedCentral

Titel: A new era for dementia epidemiology: Alzheimer’s disease, hardening of arteries, or just old age?
verfasst von: Lewis H. Kuller
Publikationsdatum: 22.06.2018
Verlag: Springer Netherlands
Erschienen in: European Journal of Epidemiology / Ausgabe 7/2018
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-018-0420-x

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2018

External validation of four dementia prediction models for use in the general community-dwelling population: a comparative analysis from the Rotterdam Study

Age-specific ALS incidence: a dose–response meta-analysis

A cross-national analysis of the association between years of implementation of opioid substitution treatments and drug-related deaths in Europe from 1995 to 2013

Will biomarker-based diagnosis of Alzheimer’s disease maximize scientific progress? Evaluating proposed diagnostic criteria

Broadening the scope of epidemiologic dementia research

Gestational age at birth and risk of intellectual disability without a common genetic cause